-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Amitivir
Category | Influenza Virus |
CAS | 111393-84-1 |
Description | Amitivir is an inosine monophosphate dehydrogenase inhibitor with activity against several influenza A and B viruses and broad antiviral activity against orthomyxoviruses and paramyxoviruses. |
Product Information
Synonyms | LY 217896; N-(1,3,4-thiadiazol-2-yl)cyanamide; Cyanamide, N-1,3,4-thiadiazol-2-yl-; 1,3,4-Thiadiazole-2-carbamonitrile |
IUPAC Name | 1,3,4-thiadiazol-2-ylcyanamide |
Molecular Weight | 126.14 |
Molecular Formula | C3H2N4S |
Canonical SMILES | C1=NN=C(S1)NC#N |
InChI | InChI=1S/C3H2N4S/c4-1-5-3-7-6-2-8-3/h2H,(H,5,7) |
InChIKey | YUCHAYRHHXJNQK-UHFFFAOYSA-N |
Boiling Point | 236.3±23.0°C at 760 mmHg |
Flash Point | 96.7°C |
Purity | 95% |
Density | 1.613±0.1 g/cm3 |
Solubility | Soluble in DMSO |
Appearance | Solid Powder |
Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
Complexity | 116 |
Exact Mass | 126.00000 |
Index Of Refraction | 1.703 |
In Vitro | The mean 50% inhibitory concentration of Amitivir inhibits six strains of type A influenzaranged from 0.37 to 1.19 μg/ml. The mean 50% inhibitory concentration of Amitivir inhibits four strains of influenza B virus ranged from 0.75 to 1.54 μg/ml. |
In Vivo | Amitivir (LY 217896) (9 mg/m2 of body surface area per day) administered in the diet, in the drinking water, by oral gavage, by intraperitoneal injection, or by aerosolization was well tolerated and protected CD-1 mice infected with a lethal dose of influenza A or B virus. |
PSA | 93.07000 |
Target | Influenza Virus |
Vapor Pressure | 0.0477mmHg at 25°C |
XLogP3-AA | 0.7 |